
|Podcasts|March 4, 2011
Preparing for Future Trends in Risk Management
Advertisement
Preparing for Future Trends in Risk Management
New legislation in the US, Europe and other countries have made product risk management a key priority for drug approval and continued marketing. To thrive in this new era, the pharmaceutical industry needs to incorporate new strategies and tactics.
Medical products companies will need to change their drug development and commercialization activities to anticipate and develop post-marketing surveillance and risk minimization activities that may be needed in the post-marketing period. Both of these activities are increasingly required by regulatory authorities throughout the world to ensure that the benefit to risk profile remains positive for patients using the medication.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
2
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
3
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
4
Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad
5



